Skip to main content
SpringerLink
Log in

Patents

Do patent applications and Cooperative Research and Development Agreements between the National Cancer Institute and industry serve the public interest?

  • Patents
  • Published:

From Nature Biotechnology

View current issue Submit your manuscript

Policy changes are needed to ensure that Cooperative Research and Development Agreements and patent applications filed by the US National Institutes of Health are aligned with the interests of the American public.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Sagal, M. W., Slowinski, G., Freese, K. & Ferguson, S. LES Nouv. 44, 41–48 (2009).

    PubMed  PubMed Central  Google Scholar 

  2. Ansher, S. S. & Scharf, R. Ann. NY Acad. Sci. 949, 333–340 (2001).

    Article  CAS  PubMed  Google Scholar 

  3. Ivy, S. P. Oncology (Williston Park) 14 (Suppl. 11), 27–29 (2000).

  4. Teicher, B. A. & Anderson, K. C. Clin. Cancer Res. 21, 939–941 (2015).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Sanchez-Serrano, I. Discov. Med 5, 527–533 (2005).

    PubMed  Google Scholar 

  6. US District Court. University of Kansas Center for Research, Inc. vs. United States of America, represented by the Department of Health and Human Services, by and through its agents the National Institutes of Health and the National Cancer Institute (2008); https://www.patentdocs.org/files/u_ks_v_us.pdf

  7. Allen, S. The Velcade story. The Boston Globe http://archive.boston.com/business/healthcare/articles/2007/05/06/the_velcade_story/ (6 May 2007).

  8. US District Court. University of Kansas Center for Research, Inc. vs. United States of America, represented by the Department of Health and Human Services, by and through its agents the National Institutes of Health and the National Cancer Institute. (2009); https://www.govinfo.gov/content/pkg/USCOURTS-ksd-2_08-cv-02565/pdf/USCOURTS-ksd-2_08-cv-02565-0.pdf

  9. US Securities and Exchange Commission. Form 10-K (2004); https://www.sec.gov/Archives/edgar/data/1002637/000104746904007316/a2130167z10-k.htm#cm1241_item_5._market_for_the_registr__ite04803

  10. Takeda to acquire Millennium for US$25.00 per share in an all cash tender offer valued at $8.8 billion. Fierce Biotech (10 April 2008); https://www.fiercebiotech.com/biotech/takeda-to-acquire-millennium-for-us-25-00-per-share-an-all-cash-tender-offer-valued-at-8-8

  11. US Securities and Exchange Commission. Form 20-F (2018); https://assets-dam.takeda.com/raw/upload/v1662727578/legacy-dotcom/siteassets/system/investors/report/sec-filings/20-F_2018-12-17.pdf

  12. US Government Accountability Office. NIH Should Publicly Report More Information about the Licensing of Its Intellectual Property (2020); https://www.gao.gov/assets/720/710328.pdf

  13. Shah, P., Vaughan, G. & Ledley, F. D. PLoS One 18, e0283887 (2023).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. SEER. Myeloma - Cancer Stat Facts (accessed 19 May 2023); https://seer.cancer.gov/statfacts/html/mulmy.html

  15. Fujisawa, M., Suehara, Y., Fukumoto, K., Takeuchi, M. & Matsue, K. Ann. Hematol. 95, 63–72 (2016).

    Article  CAS  PubMed  Google Scholar 

  16. Multiple Myeloma Research Foundation. Generic versions of Revlimid and Velcade now available for patients with multiple myeloma. MMRF Blogs (10 June 2022); https://themmrf.org/wp-content/uploads/2023/07/Treatment-Overview_patient-toolkit.pdf

  17. NIH Office of Technology Transfer. Model PHS CRADA for Extramural-PHS Clinical Research (2018); https://www.ott.nih.gov/sites/default/files/documents/docs/Model-PHS-ECT-CRADA-rev2018.docx

  18. NIH Office of Technology Transfer. Information for NIH Inventors (accessed 6 June 2023); https://www.techtransfer.nih.gov/royalty/information-nih-inventors#3

  19. Bauchner, H. J. Am. Med. Assoc. 321, 751–752 (2019).

    Article  Google Scholar 

  20. Bach, P. B. N. Engl. J. Med. 373, 1797–1799 (2015).

    Article  PubMed  Google Scholar 

  21. Polite, B. N., Ratain, M. J. & Lichter, A. S. JAMA Oncol 7, 25–26 (2021).

    Article  PubMed  Google Scholar 

  22. Blumenthal, D., Miller, M. E. & Gustafsson, L. Harv. Bus. Rev. (1 October 2021); https://hbr.org/2021/10/the-u-s-can-lower-drug-prices-without-sacrificing-innovation

Download references

Author information

Authors and Affiliations

  1. Section of Hematology/Oncology, Department of Medicine, University of Chicago, Chicago, IL, USA

    Austin Wesevich & Mark J. Ratain

Authors
  1. Austin Wesevich
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mark J. Ratain
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mark J. Ratain.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wesevich, A., Ratain, M.J. Do patent applications and Cooperative Research and Development Agreements between the National Cancer Institute and industry serve the public interest?. Nat Biotechnol 41, 1517–1519 (2023). https://doi.org/10.1038/s41587-023-02004-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41587-023-02004-2

  • Springer Nature America, Inc.

Search

Navigation